Salmeterol hydrofluoroalkane inhalation - GlaxoSmithKline
Alternative Names: Salmeterol CFC-free; Salmeterol HFA; Salmeterol HFA inhalation - GlaxoSmithKline; Salmeterol xinafoate HFA; Serevent CFC-free; Serevent Evohaler; Serevent HFALatest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 07 Oct 2011 First generic equivalent available in United Kingdom
- 02 Dec 2004 No development reported - Phase-III for Asthma in USA (Inhalation)
- 02 Dec 2004 No development reported - Phase-III for Chronic obstructive pulmonary disease in USA (Inhalation)